KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Prepaid Assets (2016 - 2026)

Pacific Biosciences Of California has reported Prepaid Assets over the past 16 years, most recently at $10.8 million for Q4 2025.

  • For Q4 2025, Prepaid Assets fell 42.53% year-over-year to $10.8 million; the TTM value through Dec 2025 reached $10.8 million, down 42.53%, while the annual FY2025 figure was $10.8 million, 42.53% down from the prior year.
  • Prepaid Assets for Q4 2025 was $10.8 million at Pacific Biosciences Of California, down from $11.5 million in the prior quarter.
  • Over five years, Prepaid Assets peaked at $18.8 million in Q4 2024 and troughed at $5.6 million in Q1 2021.
  • A 5-year average of $12.6 million and a median of $13.0 million in 2022 define the central range for Prepaid Assets.
  • Biggest five-year swings in Prepaid Assets: soared 128.58% in 2021 and later tumbled 42.53% in 2025.
  • Year by year, Prepaid Assets stood at $7.4 million in 2021, then skyrocketed by 39.15% to $10.3 million in 2022, then surged by 65.61% to $17.0 million in 2023, then increased by 10.22% to $18.8 million in 2024, then tumbled by 42.53% to $10.8 million in 2025.
  • Business Quant data shows Prepaid Assets for PACB at $10.8 million in Q4 2025, $11.5 million in Q3 2025, and $12.3 million in Q2 2025.